Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
15.9.2022 15:00:00 EEST | Business Wire | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.
Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need. Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including cardiometabolic and fibrotic complications.
INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversago’s lead program.
Dr. Glenn Crater, CMO at Inversago, stated: “This IND clearance is an important milestone for Inversago and marks the beginning of an important regulatory and clinical process in bringing a new therapeutic approach to patients suffering from Diabetic Kidney Disease.”
“We are excited to report this significant achievement for our first-in-class, peripherally-acting CB1 inverse agonist, which confirms our leadership in this field. We believe that CB1 blockers, such as INV-202, offer opportunities in multiple therapeutic areas,” added François Ravenelle, PhD, Chief Executive Officer of Inversago.
Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including Diabetic Kidney Disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs.
About Diabetic Kidney Disease
Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease. Like other chronic diseases, it is expected that multiple mechanisms are needed to achieve adequate control of this progressive disease. Inversago believes that peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. For more information, visit inversago.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005424/en/
Contact information
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.
info@inversago.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran sets intra-data center benchmark with all-new ultra-low-power LiteWave800™ LPO module10.3.2026 15:00:00 EET | Press release
Adtran today launched LiteWave800™, an ultra‑low‑power 800Gbit/s DR8 linear pluggable optics (LPO) module engineered to help data centers address the power, latency, thermal and bandwidth demands of modern AI and machine-learning (ML) workloads. As GPU clusters grow and short-reach links scale across dense server racks, operators need 800Gbit/s optics that deliver higher capacity within strict power and cooling limits. LiteWave800™ answers this challenge with a fully re-engineered architecture that significantly reduces energy consumption. Operating at just 1pJ/bit and consuming only 0.8W, it establishes a new power class for 800Gbit/s optics, delivering far lower energy per bit than today’s first‑generation LPOs and mainstream DSP-based pluggable transceivers. Adtran will showcase LiteWave800™ at OFC 2026 in Los Angeles from March 17 to 19. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310344607/en/ Adtran's LiteWave800
Verifone and Thales Unlock Seamless Global Connectivity for Payment Terminals10.3.2026 15:00:00 EET | Press release
At the core of this partnership is Thales’s leadership in eSIM management for large-scale connected devices, enabling remote connectivity provisioning and management, in line with the latest GSMA SGP.32 IoT specifications. These standards support secure and interoperable management of connectivity profiles, making it possible to deploy devices globally while maintaining full control over connectivity choices at local level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310957492/en/ Thales today announced a partnership with Verifone, a global leader in payment terminal solutions, to connect Verifone’s next-generation point-of-sale (POS) terminals using Thales eSIM technology. For Verifone, this approach transforms manufacturing and logistics. Devices can be produced in a single, standardized configuration, shipped anywhere in the world, and activated remotely once deployed. This streamlines supply chains, accelerates tim
Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices10.3.2026 15:00:00 EET | Press release
Hyperice, a high-performance wellness brand, today announced the global launch of the Hypervolt 3 line, its most advanced percussion massage technology to date. The three-device line features the Hypervolt Go 3 ($149), the Hypervolt 3 ($249), and the Hypervolt 3 Pro ($349) — achieving significant performance upgrades across the board at more accessible price points than industry competitors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310934508/en/ The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain flexibility and range of motion, accelerate warm-up before workouts, and recover quickly after activity. Hyperice has built its reputation over the last 15 years on one guiding principle: elite-level recovery technology designed to help everyone perform and move better, from professional athletes to those preparing for or recovering from the day-to-day grind. The Hypervolt 3
Nexthop AI Unveils Transformative, industry-leading Scale-out and Scale-across Switches engineered for Hyperscalers & NeoClouds10.3.2026 14:45:00 EET | Press release
Nexthop AI, the leading pioneer of highly efficient AI Networking, today launched a range of products for scale-out, scale-across and front-end applications for cloud and AI datacenters. The launch portfolio sets new standards for performance, power efficiency, and deployment speed - very critical metrics in AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310990709/en/ Nexthop AI's highly efficient scale-out and scale-across AI networking portfolio Nexthop also unveiled the Disaggregated Spine architecture - a new, highly efficient, scale-across network design developed in collaboration with a large hyperscaler. This innovative architecture decomposes the traditional monolithic chassis running proprietary software into independent, optimized, functional tiers. It features a scale-across leaf tier (data center fabric facing) and scale-across spine tier (data center interconnect facing) offering deep buffe
Nexthop AI Accelerates Into Hypergrowth With Oversubscribed $500M Series B Funding, Catapulting the Company’s Valuation to $4.2 Billion10.3.2026 14:45:00 EET | Press release
Nexthop AI, the leading pioneer of highly efficient AI Networking, today announced successful closure of an oversubscribed $500 Million Series B funding round, catapulting the company’s valuation to $4.2 Billion. This round was spearheaded by Lightspeed Venture Partners, with Andreessen Horowitz joining as a major investor, and participation from Altimeter and all existing investors. “The rapid growth of AI is forcing a fundamental rethink of data center network architecture — and that creates one of the largest infrastructure market opportunities we’ve seen in a generation, with the potential to build a $100B+ company. That conviction led us to invest in Nexthop AI from Day One,” said Guru Chahal, Partner at Lightspeed Venture Partners. “Nexthop is uniquely positioned to become the next great networking vendor by combining hyperscale-grade performance, open software, and a co-development model built in lockstep with the world’s largest AI operators.“ “AI clusters are pushing data cent
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom